Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
CEL-SCI Corporation (NYSE American: CVM) has filed Amendment No. 1 to a Form S-3 shelf registration, enabling the company to issue up to $100 million of common stock, preferred stock (including convertibles), rights, warrants and/or units on a continuous basis. Pricing, size, and underwriter details will be set in future prospectus supplements.
The document retroactively reflects the 1-for-30 reverse stock split effected 20 May 2025, which cut outstanding shares from roughly 94 million to about 3.1 million while leaving authorised share counts unchanged. CEL-SCI lists 6,882,156 post-split shares outstanding as of 4 Aug 2025; the stock last closed at $9.25.
Net proceeds are earmarked primarily to advance lead immunotherapy Multikine®. In a Phase III trial’s target subgroup (no nodal involvement; low PD-L1) Multikine delivered 73 % 5-year survival versus 45 % for standard of care (hazard ratio 0.35). The FDA has cleared a 212-patient confirmatory registration study, potentially allowing an accelerated approval filing once fully enrolled.
CEL-SCI is a late-stage biotech with no product approvals or revenue. FY-2024 net loss was $27.6 million and the auditor flagged going-concern risk. Management warns that the contemplated securities are high-risk and potentially dilutive; proceeds are needed to fund trials, operations and working capital.
Cel-Sci Corp (CVM) Form 4: Senior Vice President John Cipriano received 7,500 stock options on 07/28/25 at an exercise price of $8.20, expiring 07/27/35. Vesting occurs in three equal annual tranches beginning one year from grant. No common shares were bought or sold; the filing records an “A” code equity award rather than an open-market transaction. After the grant, Cipriano holds 38,008 derivative securities. The award is typical incentive compensation with negligible near-term cash flow or dilution impact for shareholders.
CEL-SCI Corp (CVM) – Form 4 insider transaction
Director Robert E. Watson bought 2,919 restricted shares of CEL-SCI on 25-Jul-2025 at $6.85 (prior day’s close), a cash outlay of roughly $20k. Following the purchase, Watson’s direct holdings increased to 3,733 shares. No derivative securities were involved and the filing shows the transaction was made directly with the company, suggesting an equity-based compensation or voluntary open-market style purchase rather than option exercise or planned sale. The filing does not reference any concurrent sales, options, or changes in indirect ownership.
The transaction is modest relative to CEL-SCI’s market capitalization and daily trading volume, but insider buying—especially by a board member—can signal personal confidence in the company’s prospects and may be viewed positively by investors monitoring governance alignment.